{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T07:33:02Z","timestamp":1763105582574,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progr\u00e8s en Urologie"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.purol.2018.03.008","type":"journal-article","created":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T00:59:45Z","timestamp":1523926785000},"page":"344-350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Interest of next-generation sequencing in BCG-treated high-risk bladder cancer"],"prefix":"10.1016","volume":"28","author":[{"given":"C.","family":"Jungels","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Martinez Chanza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Albisinni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mercier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"d\u2019Haene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Rorive","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Roumegu\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.purol.2018.03.008_bib0155","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","article-title":"Bladder cancer incidence and mortality: a global overview and recent trends","volume":"71","author":"Antoni","year":"2017","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.purol.2018.03.008_bib0160","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"issue":"17","key":"10.1016\/j.purol.2018.03.008_bib0165","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1002\/cncr.28147","article-title":"Recurrence of high-risk bladder cancer: a population-based analysis: burden of high-risk bladder cancer","volume":"119","author":"Chamie","year":"2013","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.purol.2018.03.008_bib0170","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.purol.2018.03.008_bib0175","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with Bacillus Calmette-Guerin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.purol.2018.03.008_bib0180","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta\u2013T1 urothelial bladder cancer patients treated with 1\u20133 years of maintenance Bacillus Calmette-Gu\u00e9rin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.purol.2018.03.008_bib0185","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0022-5347(05)64553-3","article-title":"Interobserver discrepancy using the 1998 World Health Organization\/International Society of Urologic Pathology Classification of urothelial neoplasms: practical choices for patient care","volume":"168","author":"Murphy","year":"2002","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.purol.2018.03.008_bib0190","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.urology.2005.10.028","article-title":"Review pathology in a diagnostic bladder cancer trial: effect of patient risk category","volume":"67","author":"Witjes","year":"2006","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.purol.2018.03.008_bib0195","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.eururo.2010.05.043","article-title":"Molecular grade (FGFR3\/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer","volume":"58","author":"van Rhijn","year":"2010","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.purol.2018.03.008_bib0200","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0302-2838(03)00048-4","article-title":"Do prognostic parameters of remission versus relapse after Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy exist? Analysis of a quarter century of literature","volume":"43","author":"Saint","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2018.03.008_bib0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/429213","article-title":"A decade of FGF receptor research in bladder cancer: past, present, and future challenges","volume":"2012","author":"di Martino","year":"2012","journal-title":"Adv Urol"},{"issue":"12","key":"10.1016\/j.purol.2018.03.008_bib0210","doi-asserted-by":"crossref","first-page":"e48993","DOI":"10.1371\/journal.pone.0048993","article-title":"Meta-analysis of the relationship between FGFR3 and TP53 mutations in bladder cancer. Koul H, \u00e9diteur","volume":"7","author":"Neuzillet","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.purol.2018.03.008_bib0215","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/path.2207","article-title":"FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer","volume":"213","author":"Tomlinson","year":"2007","journal-title":"J Pathol"},{"issue":"3","key":"10.1016\/j.purol.2018.03.008_bib0220","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.eururo.2008.06.013","article-title":"FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours","volume":"55","author":"van Oers","year":"2009","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.purol.2018.03.008_bib0225","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1158\/0008-5472.CAN-03-2421","article-title":"FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma","volume":"64","author":"van Rhijn","year":"2004","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.purol.2018.03.008_bib0230","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1200\/JCO.2003.05.073","article-title":"Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome","volume":"21","author":"van Rhijn","year":"2003","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.purol.2018.03.008_bib0235","doi-asserted-by":"crossref","first-page":"e13821","DOI":"10.1371\/journal.pone.0013821","article-title":"FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations mutations in bladder cancer and their potential as biomarkers for surveillance and therapy","volume":"5","author":"Kompier","year":"2010","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.purol.2018.03.008_bib0240","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.eururo.2007.12.026","article-title":"Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study","volume":"54","author":"Burger","year":"2008","journal-title":"Eur Urol"},{"issue":"22","key":"10.1016\/j.purol.2018.03.008_bib0245","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2005.05.1771","article-title":"Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas","volume":"24","author":"Hern\u00e1ndez","year":"2006","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.purol.2018.03.008_bib0250","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/j.1464-410X.2012.10996.x","article-title":"Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer","volume":"110","author":"van Rhijn","year":"2012","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.purol.2018.03.008_bib0255","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/sj.bjc.6606016","article-title":"Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo","volume":"104","author":"Lamont","year":"2011","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.purol.2018.03.008_bib0260","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S0090-4295(01)00968-2","article-title":"P53 in bladder cancer: mechanism of action, prognostic value, and target for therapy","volume":"57","author":"Slaton","year":"2001","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.purol.2018.03.008_bib0265","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1046\/j.1464-410x.1999.00217.x","article-title":"The genetics of transitional cell carcinoma: progress and potential clinical application","volume":"84","author":"Knowles","year":"1999","journal-title":"BJU Int"},{"issue":"7","key":"10.1016\/j.purol.2018.03.008_bib0270","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.urolonc.2014.07.002","article-title":"Molecular markers for urothelial bladder cancer prognosis: toward implementation in clinical practice","volume":"32","author":"van Rhijn","year":"2014","journal-title":"Urol Oncol"},{"issue":"9","key":"10.1016\/j.purol.2018.03.008_bib0275","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S1470-2045(05)70315-6","article-title":"P53 as a prognostic marker for bladder cancer: a meta-analysis and review","volume":"6","author":"Malats","year":"2005","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.purol.2018.03.008_bib0280","first-page":"784","article-title":"Two molecular pathways to transitional cell carcinoma of the bladder","volume":"54","author":"Spruck","year":"1994","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.purol.2018.03.008_bib0285","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.urolonc.2010.04.003","article-title":"Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium","volume":"28","author":"Goebell","year":"2010","journal-title":"Urol Oncol"},{"key":"10.1016\/j.purol.2018.03.008_bib0290","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1186\/s12885-016-2570-0","article-title":"PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma","volume":"16","author":"Ross","year":"2016","journal-title":"BMC Cancer"},{"issue":"33","key":"10.1016\/j.purol.2018.03.008_bib0295","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1038\/sj.onc.1208705","article-title":"FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma","volume":"24","author":"Jebar","year":"2005","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.purol.2018.03.008_bib0300","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","article-title":"Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets","volume":"72","author":"Pietzak","year":"2017","journal-title":"Eur Urol"}],"container-title":["Progr\u00e8s en Urologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708718300824?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708718300824?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T06:30:33Z","timestamp":1761114633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1166708718300824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S1166708718300824"],"URL":"https:\/\/doi.org\/10.1016\/j.purol.2018.03.008","relation":{},"ISSN":["1166-7087"],"issn-type":[{"type":"print","value":"1166-7087"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interest of next-generation sequencing in BCG-treated high-risk bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Progr\u00e8s en Urologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.purol.2018.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}